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Conundrums in neurology: diagnosing
serotonin syndrome – a meta-analysis of
cases
Ursula Werneke1,2* , Fariba Jamshidi2, David M. Taylor3 and Michael Ott4
Abstract
Background: Serotonin syndrome is a toxic state, caused by serotonin (5HT) excess in the central nervous
system. Serotonin syndrome’s main feature is neuro-muscular hyperexcitability, which in many cases is mild but
in some cases can become life-threatening. The diagnosis of serotonin syndrome remains challenging since it can
only be made on clinical grounds. Three diagnostic criteria systems, Sternbach, Radomski and Hunter classifications, are
available. Here we test the validity of four assumptions that have become widely accepted: (1) The Hunter classification
performs clinically better than the Sternbach and Radomski criteria; (2) in contrast to neuroleptic malignant syndrome,
the onset of serotonin syndrome is usually rapid; (3) hyperthermia is a hallmark of severe serotonin syndrome; and
(4) serotonin syndrome can readily be distinguished from neuroleptic malignant syndrome on clinical grounds and
on the basis of medication history.
Methods: Systematic review and meta-analysis of all cases of serotonin syndrome and toxicity published between
2004 and 2014, using PubMed and Web of Science.
Results: Two of the four assumptions (1 and 2) are based on only one published study each and have not been
independently validated. There is little agreement between current criteria systems for the diagnosis of serotonin
syndrome. Although frequently thought to be the gold standard for the diagnosis of the serotonin syndrome, the
Hunter criteria did not perform better than the Sternbach and Radomski criteria. Not all cases seem to be of rapid
onset and only relatively few cases may present with hyperthermia. The 0 differential diagnosis between serotonin
syndrome and neuroleptic malignant syndrome is not always clear-cut.
Conclusions: Our findings challenge four commonly made assumptions about serotonin syndrome. We propose
our meta-analysis of cases (MAC) method as a new way to systematically pool and interpret anecdotal but important
clinical information concerning uncommon or emergent phenomena that cannot be captured in any other way but
through case reports.
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Neuroleptic malignant syndrome, Criteria, Meta-analysis
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Background
Serotonin syndrome (SS) is a toxic state caused by sero-
tonin (5HT) excess in the central nervous system
(CNS). SS’s main feature is neuro-muscular hyperexcit-
ability, which, if severe, can become life-threatening.
The syndrome is thought to arise from 5HT1A and
5HT2 receptor stimulation and has been linked to var-
iety of drugs with direct or indirect serotonergic actions
c1]. The risk of SS is higher when two or more seroto-
nergic drugs are used in conjunction but cases caused
by a single serotonergic agent have also been reported
[1, 2]. The list of drugs associated with serotonergic
toxicity is long, although experts do not always agree.
Examples include antidepressants, lithium, opiates such as
tramadol and meperidine (pethidine), dextromethorphan,
some antiemetics such as metoclopramide and 5HT3 re-
ceptor antagonists (“setrons”). Non-antidepressant agent
with monoamine oxidase (MAO) inhibiting properties
such as MAO-B inhibitors for the treatment of Parkin-
son’s disease, the antibiotic linezolid or the contrast dye
and methylene blue can also provoke serotonin excess and
SS. Herbal medicines such as St John’s wort (hypericum
perforatum) and illicit substances such as lysergic acid
diethylamide (LSD) and 3,4-methylendioxy-methampheta-
mine (MDMA) are further examples. Even migraine medi-
cines such as triptans have been implicated, though
opinions remain divided [3, 4].
The diagnosis of SS remains challenging since it can
only be made on clinical grounds. There is no objective
diagnostic test. Three diagnostic classification systems are
available, the Sternbach (SC), Radomski (RC) and Hunter
(HC) criteria. All three classification systems try to reflect
symptoms and symptom constellations thought to be indi-
cative of SS. Whereas SC and RC draw on neuromuscular,
cognitive and autonomous symptoms, HC focuses on
neuromuscular symptoms such as clonus in its various
forms, hyperreflexia and tremor [5–7] (Table 1).
As SS is a relatively uncommon drug reaction, it can-
not be picked up easily in randomized controlled trials
(RCTs). Incidence estimates rely on adverse events
reporting. Hence, the true incidence of SS is not
known. Physicians may not even know about this con-
dition. One survey among general practitioners (GPs)
suggested an incidence of about 0.5 –1 cases per 1000
patient months of treatment. But this figure may have
been an underestimate, since 85 % of the participating
GPs were not familiar with SS [8]. We do not know
how many cases of SS are mild, moderate or severe.
Most cases of SS seem mild and self-limiting [8, 9]. In
any event, SS more likely presents on a continuum ra-
ther than in clear-cut clinical stages [10]. Yet, failure to
diagnose signs of serotonergic toxicity can turn mild
and relatively harmless drug interactions into life-
threatening catastrophic events.
Currently, we do not know how well the diagnostic
classification systems agree with each other. Neither do
we know which system performs best, despite claims
that HC is superior [1, 11].
Here, we test four commonly held hypotheses regard-
ing about the clinical features and aetiology of SS [1, 11],
which have become established “textbook knowledge”
despite their limited or partially biased evidence base.
 Hypothesis 1: HC performs clinically better than SC
and RC.
 Hypothesis 2: In contrast to neuroleptic malignant
syndrome (NMS), the onset of SS syndrome is
usually rapid.
 Hypothesis 3: Hyperthermia is a hallmark of severe SS.
 Hypothesis 4: SS can readily be distinguished from
NMS on clinical grounds and on the basis of
medication history.
Methods
We conducted a synopsis and a meta-analysis of all cases
published between 2004 and 2014. As far as possible, we
have adhered to the PRISMA guidelines in our method
(Additional file 1).
Search strategy
We searched PubMed and Thomson Reuter’s Web of
Science for all cases of likely SS, using two keywords
“serotonin syndrome” or “serotonin toxicity” and included
all cases published between 1st January 2004 and 31st
December 2014. We chose the year 2004 as a cut-off
point, because by that time all three classification systems
were available to clinicians.
Eligibility criteria and case selection
We included all cases of adult patients meeting the def-
inition of at least one of the three diagnostic systems
and in which after differential diagnostic consideration
SS emerged as the most likely diagnosis. We excluded
all cases (1) not meeting any of the diagnostic criteria
despite claiming a diagnosis of SS; (2) being etiologic-
ally uncertain despite meeting the diagnostic criteria;
(3) containing insufficient clinical information to rate;
(4) being historical; or (5) implicating first-generation
antipsychotics or concomitant Neuroleptic Malignant
Syndrome (NMS) (Additional file 2).
We abstracted all eligible cases into a new dataset,
including general patient characteristics, onset, clinical
course, mode of presentation, symptoms, diagnostic
criteria, associated medications, treatment and out-
come. Two investigators (UW and FJ or UW and MO)
independently double-rated all cases regarding HC, SC
and RC.
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Data item definitions and statistical analysis
Hypothesis 1
We established and compared the frequency of the 20
symptoms, appearing in any of the three diagnostic
criteria sets. As proxies for severity of SS, we used
rhabdomyolysis, defined by a creatine kinase ≥ 1500 mU/L
(25.5 μkat/L) or intensive care treatment.
We calculated the overall agreement between the differ-
ent diagnostic systems and estimated agreement beyond
chance with Cohen’s kappa [12]. Then, we determined how
many severe cases would have been missed by each criteria
set. We used one-way ANOVA to determine whether there
was a linear trend regarding reporting cases according HC,
SC or RC over time (between 2004 and 2014).
Hypothesis 2
We defined “time to onset” as the time between the
purported causative action and emergence of first
symptoms of SS. We compared time to onset of “acute
or invasive” cases with “sub-acute or non-invasive
cases”. The acute or invasive category included surgery/
trauma cases, overdoses and substance abuse. The sub-
acute and non-invasive category included internal
medicine and psychiatry cases.
Hypothesis 3
We included all cases with information on body
temperature and established in how many cases fever
or hyperthermia was present. We defined fever as a
temperature > 38 °C (100.4 °F) (3) and hyperthermia as
a temperature > 41.1 °C (106.0 °F) (5). We also included
cases that explicitly stated “fever”, but did not give a
temperature reading.
Hypothesis 4
We explored the frequencies of symptoms, which could
suggest either, SS or NMS. We then looked at the top ten
medications or drug combinations associated with SS.
Table 1 Sternbach, Radomski and Hunter diagnostic criteria
Sternbach Radomski Hunter
Co-incidence with the addition or increase in a
known serotonergic agent to an established
treatment regimen, at least three of the following
features present:
Coincidence with the addition or increase in a
known serotonergic agent (to an established
treatment regimen), and the development of at
least four minor or three major plus two minor
symptoms:
In the presence of a serotonergic agent,
symptom or symptom constellation:
Mental status changes (confusion, hypermania)
Agitation
Myoclonus
Hyperreflexia
Diaphoresis
Shivering
Tremor
Diarrhea
Incoordination
Fever
Major Minor
Mental
• Consciousness • Restlessness
impairment • Insomnia • Spontaneous clonus
• Inducible clonus AND agitation OR
diaphoresis
• Ocular clonus AND agitation OR diaphoresis
• Tremor AND hyperreflexia
• Hypertonic AND temperature > 38 °C AND
ocular clonus OR inducible clonus
• Elevated mood
• Semicoma/coma
Neurological
• Myoclonus • Uncoordination
• Tremor • Dilated pupils
• Shivering • Akathisia
• Rigidity
• Hyperreflexia
Vegetative
• Fever • Tachycardia
• Sweating • Tachy/dyspnea
• Diarrhea
• Hyper/hypotension
• Clinical features not an integral part of the
underlying psychiatric disorder prior to
commencing the serotonergic agent.
• Other aetiologies (e.g. infectious, metabolic or
endocrine, substance abuse or withdrawal) have
been ruled out.
• Other aetiologies (e.g. infectious, metabolic or
endocrine, substance abuse or withdrawal)
have been ruled out.
• A neuroleptic drug had not been started or
increased in dosage prior to the onset of the signs
and symptoms listed above.
• A neuroleptic drug had not been started or
increased in dosage prior to the onset of the
signs and symptoms listed above.
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Results
In the final data set we included 299 cases (Additional
file 3). 15.4 % cases related to intentional overdoses.
14 % of cases had resulted in rhabdomyolysis and 6.4 %
in death. Overall, 39.2 % of 291 patients, for whom in-
formation on treatment was available, required intensive
care (ICU).
Hypothesis 1: HC performs clinically better than SC and
RC
Confusion/consciousness impairment and agitation pre-
dominated as mental status changes. Of neurological
symptoms, tremor and hyperreflexia were most fre-
quently reported followed by muscle rigidity/hypertonia.
Myoclonus was more common than clonus. Tachycardia,
hypertension and fever were the most common auto-
nomic symptoms. In cases with rhabdomyolysis, muscle
rigidity/hypertonicity, fever and hyperthermia were sig-
nificantly more frequent. In cases requiring intensive
care, clonus, rigidity/hypertonicity, elevated temperature,
fever, hyperthermia and tachy/dyspnea significantly pre-
sented more often (Table 2).
When we applied all three classification systems to all
cases in our collection, we found that of the 299 cases,
48.8 % met all three diagnostic systems, 27.8 % both SC
and RC, 13.7 % SC only, 5.4 % HC only, 2.3 % both HC
and SC, 1.0 % both HC and RC and 1.0 % RC only.
Reporting according to diagnostic criteria changed over
time for HC and SC with a significant linear trend to-
wards HC (p = 0.02) and away from SC (p ≤ 0.05).
Reporting according to RC remained stable over time.
Agreement beyond chance between HC and SC and
HC and RC, as measured by Cohen’s kappa, was poor
for the whole sample and the subsets of cases with
rhabdomyolysis and intensive care. The agreement be-
yond chance between SC and RC was fair for the whole
sample and cases with rhabdomyolysis. It was moderate
for intensive care cases (Table 3).
HC identified fewer overdoses, rhabdomyolysis and in-
tensive care cases than SC or RC. In total, 35.7 % of all
rhabdomyolysis and 35.1 % of all intensive care cases
would not have been diagnosed as SS, adhering strictly
to HC. In the subset of cases published between 2010
and 2014, 22.7 % of rhabdomyolysis and 26.4 % of inten-
sive care cases would have been missed, adhering strictly
to HC.
Hypothesis 2: In contrast to neuroleptic malignant
syndrome (NMS), the onset of SS syndrome is usually
rapid
In our review of 236 (78.9 %) cases, for whom informa-
tion on time to onset of SS was available, only 27.5 % of
cases presented within 6 h and 44.5 % after 24 h. In
total, 40.1 % belonged to the “acute/invasive treatment”
group where pro-serotonergic drugs were administered
quickly and/or in large doses (including overdoses). In
this group, 52.2 % of cases presented within 6 h and
19.6 % after 24 h. 59.9 % belonged to the “sub-acute/
non-invasive” group where medications were more grad-
ually titrated and cross–tapered. In this group, only
11.8 % of cases presented within 6 h and 60.4 % after
24 h. All group differences were statistically significant
with p ≤ 0.01.
Hypothesis 3: Hyperthermia is a hallmark of severe SS
In our sample, where temperature was explicitly men-
tioned, fever had occurred 59.7 %. Of all cases with ex-
plicit temperature readings, only 9.2 % had temperatures
consistent with hyperthermia. Fever and hyperthermia
were significantly more common in cases with rhabdo-
myolysis or those admitted to intensive care. Nonethe-
less, about one quarter of intensive care cases would
have been missed relying on fever alone. About four
fifths would have been missed relying on hyperthermia
alone (Table 2).
Hypothesis 4: SS can readily be distinguished from
neuroleptic malignant syndrome (NMS) on clinical
grounds and on the basis of medication history
In our case collection, ten causes accounted for 83.3 %
of all SS cases. Combination of antidepressants with opi-
ates and overdoses were most common. These ten
causes accounted for 86.8 % of SS cases requiring inten-
sive care. Here, overdoses and combinations of antide-
pressants with methylene blue, opiates or linezolid
emerged as the most frequent causes (Table 4). Ten
cases implicated second-generation antipsychotics (SGA)
as the decisive triggering factor. Eight of these had oc-
curred in combination with antidepressants and two in
the context of SGA swap.
Rigidity and rhabdomyolysis, symptoms commonly as-
sociated with NMS, were also frequently seen in our
sample of SS. Rigidity/hypertonicity had occurred in
45.4 % and rhabdomyolysis in 14.0 % (Table 2).
Discussion
Our findings challenge four commonly made assump-
tions about SS, which over time have become accepted
textbook knowledge. There is only little agreement be-
tween current criteria systems for the diagnosis of SS so
that clinicians need to keep an open mind about the
diagnosis, even if diagnostic criteria not are met.
Hypothesis 1
HC may clinically be less sensitive than hitherto as-
sumed. We acknowledge that our case note collection is
inevitably subject to selection bias, but this does not in-
validate our arguments. Understanding uncommon or
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Table 3 Agreement between the three classification systems
Cases n Observed agreement (%) Agreement beyond chance (Cohen’s k)
HC vs. SC HC vs. RC SC vs. RC HC vs. SC HC vs. RC SC vs. RC
All 299 51.8 63.2 81.9 −0,10 0.20 0.30
Intensive care 114 61.4 61.4 91.2 −0.04 −0.01 0.45
Rhabdomyolysis 42 64.3 69.1 90.5 0.04 0.20 0.29
Table 2 Prevalence of symptoms of serotonin syndrome
All (n = 299) Rhabdo-myolysis
(n = 42)
No rhabdo-myolysis
(n = 257)
Intensive care
(n = 114)
No inten-sive care
(n = 177)
% Mental status changes
Mania 2.7 2.4 2.7 - 4.5
Confusion/consciousness impairment/semi coma 63.9 73.8 62.3 68.4 59.9
Coma 11.4 21.4 9.7 25.4** 2.8
Agitation/restlessness 56.1 45.2 58.0 60.5 53.7
Insomnia 9.7 -* 11.3 2.6** 14.7
% Neurological symptoms
Clonus
• Spontaneous
• Inducible
34.1
27.1
7.0
31.0
26.2
4.8
34.6
27.2
7.4
45.6**
38.6**
7.0
27.7
20.9
6.7
Eye clonus/roving eye movements
• Spontaneous
• Inducible
7.7
7.4
0.3
11.9
11.9
-
7.0
6.6
0.4
10.5
10.5
-
5.7
5.1
0.6
Myoclonus 41.5 35.7 42.4 43.9 39.5
Tremor 58.5 57.1 58.9 42.1** 70.1
Hyperreflexia 56.5 66.7 54.9 60.5 54.2
Rigidity/hypertonicity 45.4 59.5* 43.2 55.3* 40.6
Incoordination 15.1 4.8* 16.7 8.8* 19.8
% Vegetative symptoms
Diarrhea 15.1 7.1 16.7 13.2 17.5
Fevera 59.7 76.9* 56.0 74.0** 46.6
Hyperthermia > 41.1 °Cb 9.2 20.6* 6.5 17.6* 1.2
Diaphoresis 53.2 52.4 53.3 50.9 54.8
Shiver 15.1 16.7 14.8 19.3 12.4
Mydriasis 34.1 42.9 32.7 36.0 32.8
Tachy/bradycardiac 85.1 88.9 84.3 86.3 84.2
Hyper/hypotensiond 75.8 76.6 75.7 80.7 70.6
Tachy/dyspnea as measured by a breathing rate > 20 or
hypoxia
26.4 38.1 24.5 43.9** 15.9
*significant at p ≤ 0.05, **significant at p ≤ 0.01
a221 of all patients, 39 cases with rhabdomyolysis and 182 without, 100 cases with intensive care and 116 without, for whom temperature was
explicitly mentioned
b173 of all patients, 34 cases with rhabdomyolysis and 139 without, 85 cases with intensive care and 84 without, for whom actual temperature values
were recorded
c221 of all patients, 36 cases with rhabdomyolysis and 185 without, 95 cases with intensive care and 120 without, for whom actual pulse values were recorded
d194 of all patients, 30 cases with rhabdomyolysis, 164 without, 88 cases with intensive care and 102 without, for whom actual blood pressure values
were recorded
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emergent conditions that cannot be captured through
randomized controlled trials often depends on pattern
recognition from few cases. This way, for instance, the
acquired immune deficiency syndrome (AIDS) was dis-
covered [13]. It is unlikely that all cases missed by HC
were false positives. The HC originators themselves have
reported 96 % specificity for SC (compared to 97 % for
HC). This means we would only have expected 4 % false
positive cases when applying SC. Neither is the trend
towards reporting according to HC over time automatic-
ally a proof a HC superiority. This trend may simply
reflect that it has become increasingly difficult to publish
cases that do not fulfil HC.
History of the three classification systems
SC was the first classification system published in
1999, derived from 38 psychiatric inpatients [5]. SC
was criticized for being too unspecific and relying too
much on mental status changes. For instance, SC
could indicate SS without any neuromuscular symp-
tom, if a patient presented with confusion, agitation
and elevated temperature.
In 2001, Radomski refined SC based on a review of 62
cases, including Sternbach’s original 38 cases [6]. RC
differentiated between major and minor symptoms of SS
and added rigidity to the neuromuscular symptoms.
In 2003, Dunkley et al. released the HC based on a
review of 2222 cases of overdoses with selective sero-
tonin reuptake inhibitors (SSRIs) [7]. This classification
focused on neuromuscular symptoms to a far greater
extent than the other two classification systems. HC
introduced clonus in its various forms (spontaneous,
inducible and ocular). At the same time, HC removed
myoclonus from the symptom list. The HC originators
reported their classification system as more sensitive
and specific than the other two classification systems.
Is there a gold standard for diagnosing SS?
Rather than being a tangible physical quantity such as
body temperature or blood glucose, SS is an abstract
construct made up of various conceptual, elements
(items). In this way, the three classification systems are
similar to a psychometric scale that might measure a
construct such as quality of life. As any psychometric
measurement tool, all three classification systems have
tried in various ways to identify symptoms or symptom
constellations that capture best “the nature of what is
being measured” and “the relationship of that variable
to its purported cause” [14]. In the case of SS, we meas-
ure CNS hyperexcitability and try to relate this to a
purported drug-induced serotonin excess.
As CNS hyperexcitability can manifest itself in many
ways, it may be difficult to establish a “true” gold stand-
ard for the diagnosis of SS. HC, the latest classification
system in use, has reported superior sensitivity and spe-
cificity though. In these terms, HC should be best at
both picking up cases and not picking up false positive
cases. This has led to wide-spread endorsement of HC
as the gold standard for the diagnosis of SS [1, 11]. It
has also been suggested that reports of cases of SS that
have not met HC are of poor scientific value [15]. Yet,
the purported HC superiority is based on one study only.
This may not be sufficient to underpin HC superior val-
idity since “the burden of evidence in testing construct
validity arises not from a single powerful experiment,
but from a series of converging experiments” [14].
One concern regarding validity is that HC was derived
exclusively from SSRI overdoses. Although HC is based
on many more cases than SC and RC, the confinement
to overdose cases suggests that HC may not automatic-
ally be generalizable to non-overdose states of serotonin
excess, where symptoms may be less clear-cut than in
acute poisonings. A second concern is that a proportion
of the cases used to derive HC was then also used to
validate HC. Verifying a construct, in this case SS, by
including the same data, which was used to derive the
construct in the first place, will lead to an overestimate
of its validity [16]. Thirdly, HC may not perform well in
patients with other underlying neurological pathologies.
Hyperreflexia or clonus, two essential HC symptoms,
may not occur in patients with peripheral neuropathy
where nerve damage “masks upper motor neuron signs”
[17]. Equally, reflexes or clonus may not be elicitable in
Table 4 Usual suspects? Top 10 causes of serotonin syndrome
Cause All cases
(n = 299)
Accounting for ICU
cases (n = 114)
% %
Combination antidepressant - opiate 16.1 10.5
Overdose 15.4 26.3
Combination antidepressant with
another potentially serotonergic
agenta
13.0 7.9
Combination of different
antidepressants
7.7 5.3
Combination antidepressant - linezolid 7.0 9.6
Swap antidepressants 6.4 4.4
Combination antidepressant –
methylene blue
5.4 11.4
Start of antidepressants 4.7 -
Substance misuse 4.3 8.8
Start/ discontinuation of second
generation antipsychotics in the
presence of another pro-serotonergic
agenta
3.3 2.6
aIncluding agents such as dextromethorphan, SNRI used for other purposes
(milnacipran, sibutramine), triptanes, antiemetics (metoclopramide, setrones);
other agents affecting the metabolism of antidepressants
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patients with severe SS who have developed substantial
muscle rigidity [1].
Clinically, particularly when a condition is life threat-
ening, it may be better to err on the side of caution and
temporarily withdraw a purported offending agent, until
the differential diagnosis is clarified and appropriate ac-
tion can be taken. The alternative of refusing to take into
account symptoms because they do not meet HC and
continuing a potentially harmful agent seems less safe.
In many such cases, it may be possible to reinstate treat-
ment with serotonergic drugs, once the SS has resolved
and measures are taken to prevent the precipitating
event in the future. Such measures include avoiding fu-
ture overdoses, discontinuing opiates with serotonergic
properties or withdrawing serotonergic antidepressants
in good time prior to administration of methylene blue
and linezolid.
Hypothesis 2
The claim that contrary to neuroleptic malignant syn-
drome (NMS), the onset of SS is usually rapid is based
on one review of 41 cases with SS published between
1995 and 1999 [18]. In this case collection, 61.5 % pre-
sented with six hours of ingestion of the causative agent
and only 25.6 % later than 24 h. Thus, SS may develop
quickly or slowly, depending on the context in which it
occurs. Our results fit with the observation that the
onset of linezolid-associated SS may be delayed in
elderly [19]. Whether SS develops quickly or slowly, may
to a large extent depend on pharmacokinetic factors.
Although polypharmacy is an important etiological
factor in the development of SS per se, dose and speed
of distribution may determine its severity. It remains
also uncertain whether SS typically resolves much faster
than NMS [20]. Rather, time to SS resolution may
depend on the half-lives of the implicated agents.
Hypothesis 3
Fever is considered a hallmark of SS and hyperthermia.
To be more precise, a temperature > 41.1 °C, a hallmark
of severe SS [1]. Elevated temperature in SS is thought
to arise from a loss of physiologic control of temperature
regulation (leading to hyperthermia) rather than pyrogen
mediated upregulation of the hypothalamic thermostat
(pyrexia/hyperpyrexia) [20]. It is unclear, why some SS
cases develop hyperthermia and others do not. In the
context of SS, hyperthermia is linked to increased muscle
activity as consequence of hyperexcitability and direct
serotonergic effects on the muscle [1, 21, 22]. Naturally,
these factors are subject to biological variability. Psy-
chological and environmental factors such as exercise,
heating, apprehension and excitement have shown to
precipitate serotonin-mediated hyperthermia in suscep-
tible animals [22].
Hypothesis 4
We tend to think of neuroleptic malignant syndrome in
the context of antipsychotics and of serotonin syn-
drome in the context of antidepressants. Yet, the dis-
tinction between NMS and SS is less clear-cut in agents
which have both, antidopaminergic and serotonergic,
properties. Possibly, NMS and SS are part of the same
pathology rather than two different pathological entities.
This could explain why rigidity/hypertonicity has emerged
as a key symptom of SS. This could also explain why even
severe SS is associated with rhabdomyolyis. SS and NMS
are both associated with neuromuscular hyperexcitability.
Subcortical dopaminergic and serotonergic nuclei ana-
tomically overlap and share many afferent and efferent
projections [23]. Indeed, the “atypicality” of SGAs is to
some extent based on their 5HT2 antagonistic and 5HT1
agonistic properties, which may allow more dopaminergic
activity in the nigrostriatal system [24]. Sudden changes in
SGA mediated serotonergic activity may precipitate ex-
treme changes in dopamine neurotransmission, resulting
in symptoms usually associated with NMS.
Conclusions
Our findings challenge four commonly made assump-
tions about SS, which over time have become accepted
knowledge. Two of these assumptions were based each
on one published study which was then successively
quoted. As HC may not be superior to the other avail-
able classification systems clinicians should keep an
open mind about the diagnosis, even if HC are not met.
Not all cases are of rapid onset and only relatively few
cases present with hyperthermia. The differential diagno-
sis between SS and NMS is not always clear-cut. Both
conditions overlap in symptoms and many drugs have
both dopamine and serotonin modulating properties.
For the diagnosis of SS, focussing on aetiology may be
more important than relying on symptoms or symptom
constellations. Aetiological considerations are important,
because patients with symptoms of serotonin syndrome
turn to emergency rooms for help rather than the original
prescriber. Understanding the aetiology is also crucial
when deciding on whether to re-challenge with a pur-
ported offending agent or not.
On the one hand, it is important to withhold drugs
likely to cause serious adverse effects. On the other hand,
it is important not unnecessarily to withhold medicines
patients need for exaggerated fear of serotonin syndrome.
Whereas methods for reviewing intervention and epi-
demiological studies are well developed, there are no
comparable accepted methods for reviewing anecdotal
clinical data. Ignoring such data due to methodological
concerns such as selection bias is not an option, when
uncommon but clinically significant phenomena can
only be identified from cases. Indeed, up to 50 % of our
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current guidelines may largely rely on lower level evidence
and expert opinions [25, 26]. We propose our method to
meta-analyse cases (MAC) as a new way systematically to
collate and analyse anecdotal, but important, clinical infor-
mation. This way, we may be able to improve the story we
can tell from the evidence at hand [27].
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